Skip to content

10 results for "Meta-analysis: What did research on Addiction find in January 2026?"

Psychedelics in psychiatric treatment: a literature review

Quality in Sport January 26, 2026 Adam Wolski, Ewa Szplit, Mikołaj Franciszek Patalong et al.

Background: Psychedelic substances have been used for millennia in religious and healing contexts and have recently re-emerged as subjects of scientific interest due to advances in neuroscience and psychiatry. Research suggests that psychedelics may address limitations of conventional psychiatric treatments, particularly in disorders such as major depressive disorder, PTSD, substance use...

THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS

International Journal of Innovative Technologies in Social Science January 23, 2026 Jakub Klepacz, Radosław Swędrak, Marzena Swojnóg et al.

The escalating global burden of mental health disorders, coupled with the stagnation of innovation in traditional monoaminergic pharmacotherapy (e.g., SSRIs), has precipitated a critical need for novel therapeutic paradigms. This article presents a comprehensive systematic review of the so-called "Psychedelic Renaissance," focusing on the clinical resurgence of classical serotonergic...

Insights from the psychedelic experience integration session: Verbatims differentiate 3-month abstinence in alcohol use disorder with depressive symptoms

Journal of Affective Disorders January 19, 2026 Maria Garcia Garcia, Dahbia Belahda, Carine Graux et al.

Responders were distinguished by narratives of inner dialogue and adaptive coping, while non-responders emphasized sensory and affective descriptions and suppressive coping. Inner dialogue may constitute a distinct therapeutic mechanism, highlighting the importance of preparation and integration in psilocybin-assisted psychotherapy.

Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data.

CNS Drugs January 17, 2026 Gaëlle Rached, Anna Campana, Dimitri Fiani et al. 1 citation

Monoamine oxidase inhibitors (MAOIs) remain an important option for patients with treatment-resistant depression (TRD) and other psychiatric conditions, despite potentially serious drug-drug interactions and associated dietary tyramine restrictions. However, they are rarely prescribed in patients with comorbid substance use disorders (SUDs) due to concerns about potential drug interactions and...

Ibogaine for Opioid Use Disorder: An Unrecognized Risk.

Journal of Addiction Medicine January 15, 2026 Dale Terasaki, Nathan Sackett, Andrew A. Monte

The psychedelic substance, ibogaine, has garnered growing interest among policymakers, researchers, and the public in its potential use for opioid use disorder (OUD). Many states are allocating significant funds to investigate it further. However, some proponents of ibogaine are framing it in opposition to (versus complementary to) standard, mortality-reducing medications for OUD (MOUD)....

Psychedelics for the Treatment of Substance Use Disorders: A Narrative Review of the Literature.

Substance use & addiction journal 2026 Olivia Marcus, Brian Rush

There is an increasing interest in the use of psychedelics for the treatment of substance use disorders (SUDs) and to improve overall health and wellbeing. We aimed to update and complement research syntheses that have focused only on results from clinical trials by synthesizing the research across diverse methods to discuss implications from a broad and multi-faceted literature. We conducted a...

The therapeutic potential of ayahuasca in depression, generalized anxiety, and substance use disorders: modulation of the depressive burden in a longitudinal study.

Frontiers in Psychiatry 2026 Gláucio Silva Camargos, Geraldo Magela De Faria Júnior, Marcelo Lourenço et al.

This longitudinal observational study evaluated changes in depressive symptoms associated with ritualistic ayahuasca use in patients diagnosed with depressive disorders, as well as depressive burden in individuals with anxiety and substance use disorders. The research was conducted with 280 adults treated at clinics in the northwestern region of the state of São Paulo, under the jurisdiction of...

Partydrogen im Überblick

Psychopharmakotherapie 2026 Antonia Bendau, Felix Betzler, Twyla Michnevich et al. 1 citation

Party drugs encompass a broad spectrum of legal and illegal psychoactive substances used in party settings such as clubs, festivals, raves or private gatherings to modulate mood, perception, social interaction and bodily states. Most commonly, alcohol and cannabis are consumed, followed by amphetamine, MDMA (“ecstasy”), cocaine and ketamine. Synthetic cathinones, GHB/GBL (“liquid ecstasy”),...

Possible Effects of MDMA on Vehicle Driving Competencies

Transportation research procedia 2026 Samuel Hubočan, Matúš Madleňák

Safety and security in traffic is a fundamental need of every road user. There are many factors that have a direct impact on this need. It can be assumed that vehicle driving competencies represent one of these factors. A vehicle driver should be vigilant, decisive and capable of practical use of traffic rules implied by the legal system. Addictive substances can disrupt driver’s capabilities...

Sleep alterations in substance use disorders: a systematic review and meta-analysis.

EClinicalMedicine 2026 Henrique Nunes Pereira Oliva, Tiago Paiva Prudente, Alisson M Paredes Naveda et al. 5 citations

Sleep disturbances are common in individuals with substance use disorders (SUDs), often persisting beyond initial abstinence and hindering recovery. However, the underlying sleep abnormalities warrant further investigation, particularly given mixed findings regarding specific substances. This systematic review and meta-analysis aimed to identify sleep-related abnormalities associated with...